Description
Anti-Interferon Gamma Antibody, Non-Fucosylated (BioBet-1026ZP) is a human monoclonal IgG antibody against Interferon gamma. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Autoimmune Diseases; Inflammatory Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Interferon gamma antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IFNG
Full Name
interferon, gamma
Background
This gene encodes a member of the type II interferon family. The protein encoded is a soluble cytokine with antiviral, immunoregulatory and anti-tumor properties and is a potent activator of macrophages. Mutations in this gene are associated with aplastic anemia.
Alternative Names
IFNG; interferon, gamma; IFG; IFI; interferon gamma; IFN-gamma; immune interferon
Gene ID
3458
UniProt ID
Q9UK05
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IFNG include Hepatitis C Virus and Tuberous Sclerosis 2.
Related Pathways
Its related pathways are Folate Metabolism and Tuberculosis.
Function
Produced by lymphocytes activated by specific antigens or mitogens. In addition to the antiviral activity of ifn-gamma, it also has important immune regulation functions. It is a strong activator of macrophages, has an anti-proliferation effect on transformed cells, and can enhance the antiviral and antitumor effects of type I interferon.
Post-translational modifications
Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1026ZP
Description
NI-0501 is a fully human monoclonal antibody that neutralizes interferon gamma, a cell-signaling protein believed to play a pivotal role in the development of HLH. In the ongoing Phase II study, NI-0501 was initially administered to patients showing unsatisfactory response or intolerance to conventional therapies including chemotherapy, immune-suppressive medicines, and immune-depleting drugs. The approved amendment to the protocol allows NI-0501 to be administered to patients as a first-line treatment before any other intervention.
Antibody Indication
Autoimmune Diseases; Inflammatory Diseases
Autoimmune Diseases; Inflammatory Diseases
